The first thing you see on the Atomic Alchemy website is a black-and-white photograph of a glowing, blue Cherenkov radiation pool. It's an arresting, almost beautiful image of a thing most people associate with danger and decay. The second thing you see is the company's tagline, set in a clean, sans-serif font: "Building scalable U.S. radioisotope production capabilities." The pairing is the company in miniature: a hard, physical, and historically intimidating technology, framed as a solution to a quietly critical supply problem. It's not an app you download. It's a reactor you build.
Atomic Alchemy's product is the radioisotopes themselves. These unstable atoms, produced by irradiating target materials inside a reactor, are the active ingredients in millions of cancer treatments and diagnostic scans every year. They are also essential for industrial radiography, scientific research, and powering deep-space probes. For decades, the U.S. has been largely dependent on foreign sources, primarily aging reactors in Canada and Europe, for its supply. Atomic Alchemy's bet is that this dependency is a national vulnerability, and that a new generation of small, dedicated, non-power reactors can carve out a domestic niche.
The wedge is a dedicated reactor
Most commercial radioisotopes are byproducts of large, multi-purpose nuclear reactors designed for electricity generation. Atomic Alchemy's approach, as described in its public filings, is different. It is focused on the Versatile Isotope Production Reactor, or VIPR, a 15-megawatt thermal light-water reactor designed from the ground up to make isotopes [ANS / Nuclear Newswire, 2025-11-14]. The company has requested permission from the Nuclear Regulatory Commission to build four such non-power reactors at the Idaho National Laboratory [ANS / Nuclear Newswire, 2025-11-24].
This is the technical wedge. A reactor optimized for isotope production can, in theory, be more flexible, efficient, and reliable for this single purpose than a massive power plant running a side business. It also represents a specific regulatory and operational path. The company already holds an NRC license to process radium-226 at its Idaho Falls laboratory [World Nuclear News]. The goal is to create a bank of these small reactors, a scalable, U.S.-based factory for the invisible particles that fight disease and enable exploration.
A founder with four decades in the core
The company is the vision of Thomas Eiden, a nuclear engineer with over four decades of experience in power generation and project development [LinkedIn, Thomas Eiden, 2026]. His background is not in software or consumer startups, but in the gritty, long-cycle world of national laboratories and reactor core design [thomaseiden.com]. On a podcast appearance, he has spoken about the challenges of nuclear regulation and the potential for innovation in nuclear medicine, framing the radioisotope supply chain as a problem of engineering and policy, not just science [Plugged In Podcast #35].
This founder-market fit is stark. Atomic Alchemy is not a company that pivoted into nuclear tech; it is a nuclear tech company from its inception. Eiden's public engagement is focused on the specifics of production and regulation, a tone that matches the company's target customers: radiopharmacies, research institutions, and government agencies that need certainty, not hype.
The Oklo acquisition and the path to scale
In February 2025, Atomic Alchemy's path changed. It was acquired by Oklo Inc., the advanced fission company, in an all-stock transaction valued at an estimated $25 million [PrivSource, Unknown] [Businesswire, 20250305]. The deal was framed as a strategic combination: Oklo gets a foothold in the isotope production market and a team with deep regulatory experience, while Atomic Alchemy gains the capital and backing of a publicly-traded company with its own ambitious reactor development plans.
The acquisition structure suggests Atomic Alchemy will continue to operate as a distinct subsidiary under its own brand. The logic is clear. Oklo's long-term vision involves building and operating its own advanced reactors; those reactors could, in the future, also serve as sources for isotope production. For now, Atomic Alchemy provides a near-term revenue opportunity and a specialized team that understands the isotope market's unique demands.
| Entity | Role | Key Detail |
|---|---|---|
| Thomas Eiden | Founder & CEO | Nuclear engineer with 44 years in power generation and project development [LinkedIn, Thomas Eiden, 2026]. |
| Oklo Inc. | Acquirer (2025) | Advanced fission company that acquired Atomic Alchemy in an all-stock deal [Businesswire, 20250305]. |
| Y Combinator | Investor (Seed) | Participated in the startup's early seed funding round [Y Combinator]. |
| U.S. Nuclear Regulatory Commission | Regulator | Granted license for radium-226 processing; application for four VIPR reactors pending [World Nuclear News] [ANS / Nuclear Newswire, 2025-11-24]. |
The risks in a hardened market
Building a new nuclear facility in the United States is one of the most capital-intensive and legally complex endeavors imaginable. Atomic Alchemy's bet rests on navigating this gauntlet successfully. The risks are not subtle.
- Regulatory friction. The NRC application process for four new reactors, even small, non-power ones, is measured in years, not months. Any delay or redesign can burn capital and push the business case further into the future.
- Capital intensity. While the Oklo acquisition provides a backer, the actual construction of multiple reactors represents a financial commitment far beyond the startup's initial ~$650,000 in seed funding [CB Insights]. Oklo's own ability to fund this build-out will be tested.
- Market competition. The company is not competing against other startups, but against entrenched, subsidized international producers and a handful of large domestic players. Competing on cost alone is a difficult proposition; reliability and security of supply must be the compelling differentiators.
The company's answer to these risks is its focus and its partnership. By specializing in isotope production and aligning with Oklo, it aims to be more agile and purpose-built than the incumbents. Its location at the Idaho National Laboratory provides a supportive ecosystem and pre-existing nuclear infrastructure.
What to watch in Idaho
The next milestones for Atomic Alchemy are concrete and regulatory. The NRC's decision on the permit for the four VIPR reactors will be the most significant signal. A green light would validate the technical and safety approach and unlock the next phase of capital deployment. A rejection or a request for major revisions would reset the timeline considerably.
Second, watch for the first commercial isotope shipments from its existing licensed facility. Proving it can reliably produce and distribute even small quantities of material would be a crucial traction signal to the medical and research communities it hopes to supply [Atomic Alchemy].
Finally, the integration with Oklo will be telling. The press release called Atomic Alchemy a "wholly-owned subsidiary" but said it would continue operating under its own brand [Businesswire, 20250305]. The success of this model,autonomous expertise within a larger capital structure,will determine whether this is a true acquisition of capability or merely an asset purchase.
The cultural question Atomic Alchemy is answering is not about convenience or entertainment. It's about resilience. In an era of fragmented global trade and heightened geopolitical tension, which supply chains are too critical to leave offshore? The company's entire premise is that the materials used to diagnose and treat cancer, to inspect aircraft wings, and to power missions beyond our solar system belong on that list. It is a bet on rebuilding industrial sovereignty, one unstable atom at a time.
Sources
- [American Nuclear Society / Nuclear Newswire, November 2024] Oklo plans to acquire radioisotope firm Atomic Alchemy for $25 million in shares | https://www.ans.org/news/article-5822/oklo-plans-to-acquire-radioisotope-firm-atomic-alchemy-for-25-million-in-shares/
- [ANS / Nuclear Newswire, 2025-11-14] Working on its 15-MWt light water Versatile Isotope Production Reactor (VIPR) | https://www.ans.org/news/article-6564/oklo-plans-to-acquire-radioisotope-firm-atomic-alchemy-for-25-million-in-shares/
- [ANS / Nuclear Newswire, 2025-11-24] Requested permission from the NRC to build four nonpower reactors for a radioisotope production facility at Idaho National Laboratory | https://www.ans.org/news/article-6564/oklo-plans-to-acquire-radioisotope-firm-atomic-alchemy-for-25-million-in-shares/
- [Atomic Alchemy] Building scalable U.S. radioisotope production capabilities | https://www.atomicalchemy.us/
- [Businesswire, 20250305] Acquired by Oklo for $25 million in an all-stock transaction on February 28, 2025 | https://www.businesswire.com/news/home/20250305954224/en/
- [CB Insights] Total raised $650K, supplies high-value isotopes | https://www.cbinsights.com/company/atomic-alchemy/financials
- [LinkedIn, Thomas Eiden, 2026] Thomas Eiden has 44 years of experience in Power Generation, Project Development, Oil & Gas and Process Industries | https://www.linkedin.com/in/thomas-eiden
- [Plugged In Podcast #35] Thomas Eiden on Nuclear Regulations and Nuclear Medicine | https://www.instituteforenergyresearch.org/nuclear/35-thomas-eiden-on-nuclear-regulations-and-nuclear-medicine/
- [PrivSource] Acquired by Oklo for $25 million in shares (estimated) | https://intellectia.ai/news/stock/oklo-acquires-atomic-alchemy-for-25-million
- [World Nuclear News] Has a license from the NRC to receive, possess, use, store, and conduct chemical and/or mechanical processing involving radium-226 | https://www.world-nuclear-news.org/Articles/Oklo-to-acquire-radioisotope-producer-Atomic-Alchemy
- [Y Combinator] We produce cancer-curing materials used in nuclear medicine | https://www.ycombinator.com/companies/atomic-alchemy